WUXI XDC (02268) announced its 2025 financial results, reporting revenue of approximately RMB 5.944 billion, a year-on-year increase of 46.7%. Gross profit reached about RMB 2.139 billion, up 72.5% compared to the previous year. Adjusted net profit attributable to owners of the company amounted to roughly RMB 1.559 billion, reflecting a growth of 69.9%. Net profit rose by 38.4% to RMB 1.48 billion.

The group's total backlog also expanded significantly, growing by 50.3% from USD 991 million as of December 31, 2024, to USD 1.489 billion by December 31, 2025.

The company stated that its CRDMO business maintained strong momentum throughout 2024 and 2025, with operations continuing to expand actively and global demand for its services increasing. As of December 31, 2025, leveraging its comprehensive CRDMO capabilities and facilities equipped with end-to-end services from drug discovery to commercialization, the group had served a cumulative total of 643 clients worldwide through its integrated service offerings. The group has successfully secured 18 Process Performance Qualification (PPQ) projects and one commercial project to date.

The increase in revenue was primarily driven by: (i) continued robust development in the global Antibody-Drug Conjugate (ADC) and broader bioconjugate market, leading to growth in both client numbers and project volume; (ii) the company's solid position as a leading ADC CRDMO service provider, which helped increase its market share; and (iii) the steady progression of its projects into later stages, which typically generate higher contract values.